Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Topvision Eye Specialist BhdXKLS:0332 61 3-Year EBITDA Growth Rate is -5.60% as of Jun. 2026. GuruFocus rates XKLS:0332 with a GF Score™ of 61/100 and a GF Value™ of RM0.27 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 523 Healthcare Providers & Services companies, Topvision Eye Specialist Bhd ranks worse than 78.01% on this metric.
During the past 12 months, Topvision Eye Specialist Bhd's average EBITDA Per Share Growth Rate was 44.80% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -5.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 6.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Topvision Eye Specialist Bhd was 32.60% per year. The lowest was -5.60% per year. And the median was 17.00% per year.
Topvision Eye Specialist Bhd (XKLS:0332) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Topvision Eye Specialist Bhd 3-Year EBITDA Growth Rate Related Terms
XKLS:0332 vs HCA, THC, EHC: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Topvision Eye Specialist Bhd's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Topvision Eye Specialist Bhd 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Topvision Eye Specialist Bhd's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Topvision Eye Specialist Bhd's 3-Year EBITDA Growth Rate falls into.
Topvision Eye Specialist Bhd 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -5.60% mean?
Topvision Eye Specialist Bhd (XKLS:0332) has a 3-Year EBITDA Growth Rate of -5.60% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Topvision Eye Specialist Bhd and its competitors. According to the industry distribution chart, Topvision Eye Specialist Bhd ranks #408 out of 523 companies in the Healthcare Providers & Services industry, placing it in the top 78%.
Is Topvision Eye Specialist Bhd's 3-Year EBITDA Growth Rate too high?
Topvision Eye Specialist Bhd's current 3-Year EBITDA Growth Rate is -5.60%. Based on the distribution chart, Topvision Eye Specialist Bhd ranks #408 out of 523 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Topvision Eye Specialist Bhd has a GF Score™ of 61/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Topvision Eye Specialist Bhd's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Topvision Eye Specialist Bhd ranks #408 out of 523 companies for 3-Year EBITDA Growth Rate. This places Topvision Eye Specialist Bhd in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 9.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 9.90, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Topvision Eye Specialist Bhd and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Topvision Eye Specialist Bhd's current 3-Year EBITDA Growth Rate is -5.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Topvision Eye Specialist Bhd stock overvalued right now?
Based on GuruFocus' analysis, Topvision Eye Specialist Bhd (XKLS:0332) is currently considered Significantly Undervalued. The stock's GF Value™ is RM0.27, compared to a current price of RM0.18 — trading 35.2% below its estimated fair value. The current 3-Year EBITDA Growth Rate is -5.60%. Topvision Eye Specialist Bhd's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Topvision Eye Specialist Bhd (XKLS:0332), the current 3-Year EBITDA Growth Rate is -5.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Topvision Eye Specialist Bhd (XKLS:0332) Overvalued in 2026?
Based on GuruFocus' analysis, Topvision Eye Specialist Bhd stock appears to be undervalued.
The current stock price of RM0.18 is trading 35.2% below its estimated GF Value™ of RM0.27.
GuruFocus considers Topvision Eye Specialist Bhd to be Significantly Undervalued.
Key valuation signals for XKLS:0332:
3-Year EBITDA Growth Rate: -5.60%
GF Value™: RM0.27 vs. price of RM0.18 (35.2% below fair value)
No single metric tells the full story. See the XKLS:0332 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Topvision Eye Specialist Bhd is principally involved in the provision of ophthalmology services and related medical consultancy services. The company is also engaged in the marketing of eye supplements and health food products. The company derives a majority of its revenue from its ophthalmology services business, providing treatments for general as well as complex eye diseases. Geographically, it operates in Malaysia.
61GF Score
Get the complete analysis for XKLS:0332
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0332 has been successfully added to your 
